ORLANDO – A combination of daratumumab (Darzalex) with lenalidomide and dexamethasone (len/dex) was associated with a high overall response rate, including stringent complete responses, in patients with heavily pretreated relapsed/refractory multiple myeloma.
Daratumumab was recently approved by the Food and Drug Administration as monotherapy in patients with relapsed/refractory multiple myeloma.
Dr. Torben Plesner of Vejle Hospital and the University of Southern Denmark in Vejle, who dosed the first patient with daratumumab in 2007, discusses updated findings from a phase I/II trial of the daratumumab and len/dex combination.